ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03454646
Recruitment Status : Not yet recruiting
First Posted : March 6, 2018
Last Update Posted : March 6, 2018
Sponsor:
Information provided by (Responsible Party):
University Hospital, Bordeaux

Brief Summary:

Cholinesterase inhibitors (CI) remain the only drugs with a recognized efficacy in mild to moderate Alzheimer's disease (AD) in spite of enormous research efforts. However, these drugs presented as "symptomatic treatment" of AD are considered as having only a weak effect on the course of AD. The reimbursement of these drugs is regularly challenged due to the lack of evidence for the impact of these drugs on milestones stages of AD evolution (survival without severe dementia, restriction in Basic Activities of Daily Living - BADL) and on major consequences in public health (hospitalization and institutionalization). The great majority of previous randomized controlled trials conducted with CI have had a too short duration and the end points were limited to cognition (ADAS Cog scale), IADL (Instrumental Activities of Daily Living) function and Global Impression of Change. New evidences from the DOMINO trial (1) conducted in UK, independently of the pharmaceutical industry, showed that the true effect of CI might be more to avoid or to delay the cognitive or functional decline in AD than to improve patients; the institutionalisation (2) was also delayed. However, this trial was conducted in patients with moderate to severe AD, and the interest of the drugs at the mild to moderate stage remains questionable.

The investigators have shown that a good surrogate marker of survival without severe dementia would be an increase of ADAS Cog scale of more than six points (3). A post hoc reanalysis of the pivotal RCT with two CI showed that in mild to moderate patients, CI was associated with a 15% decrease of patients with a deterioration of ADAS-Cog of more than six points in six months. Thus at the beginning of dementia the real effect of CI might be more of delaying the cognitive and functional decline, than to improve the patients. The main objective of the SOS trial is to demonstrate that the benefit of CI at the early phase of dementia is the same as at the later phase.


Condition or disease Intervention/treatment Phase
Alzheimer Disease Cholinesterase Inhibitors Drug: cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine) Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1205 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Therapeutic Strategies With Cholinesterase Inhibitors: Stop or Still (SOS) Trial
Estimated Study Start Date : March 15, 2018
Estimated Primary Completion Date : March 15, 2018
Estimated Study Completion Date : September 15, 2021


Arm Intervention/treatment
Experimental: Group randomized for continuing treatment

Group who continues the cholinesterase inhibitors (CI). The treatment is one of the CI (donepezil, galantamine or rivastigmine) with market authorization and commercialized for more than 15 years in France. The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual.

All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.

Drug: cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)

The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All the recruited patients will be treated by CI according to the recommendations of the French HAS and the clinician's habits to choose the type of CI and adjust the dosage. After a 6-month period under CI treatment, patients will be classified according to the evolution of the Mini Mental State Examination (MMSE) as "non-responders" or responders.

Responders patients will continue their treatment according to the habits of the clinician. Non-responder patients will be included in the RCT, with individual randomization in two groups: one group who stops the CI, one group who continues the CI. All randomized patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.


No Intervention: Group randomized for stopping treatment
Group who stops the CI. No placebo will be given, over 2 years All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.



Primary Outcome Measures :
  1. The primary outcome is a combination of complete BADL dependency in bathing and dressing and/or institutionalization or death at 2 years after randomization. [ Time Frame: at 30 months after patient's inclusion ]

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

    For dependency in bathing and dressing, although it could be considered as less objective, we choose a level of total dependency, easy to assess with very low risk of misinterpretation.



Secondary Outcome Measures :
  1. BADL dependency will be evaluated by the clinician using the BADL scale from Katz [17]. [ Time Frame: at inclusion ]

    Each of the components of the combined primary outcome, as defined above, analyzed separately.

    As previously demonstrated, bathing and dressing are the first ADL losses, also defined by Katz et al. as the thresholds of disability [17] [18]. A total limitation in bathing and dressing will be considered (each item is coded from 0 - no limitation, to 2 - total limitation).


  2. BADL dependency will be evaluated by the clinician using the BADL scale from Katz [17]. [ Time Frame: at 6 months ]

    Each of the components of the combined primary outcome, as defined above, analyzed separately.

    As previously demonstrated, bathing and dressing are the first ADL losses, also defined by Katz et al. as the thresholds of disability [17] [18]. A total limitation in bathing and dressing will be considered (each item is coded from 0 - no limitation, to 2 - total limitation).


  3. BADL dependency will be evaluated by the clinician using the BADL scale from Katz [17]. [ Time Frame: at 12 months ]
    Each of the components of the combined primary outcome, as defined above, analyzed separately As previously demonstrated, bathing and dressing are the first ADL losses, also defined by Katz et al. as the thresholds of disability [17] [18]. A total limitation in bathing and dressing will be considered (each item is coded from 0 - no limitation, to 2 - total limitation).

  4. BADL dependency will be evaluated by the clinician using the BADL scale from Katz [17]. [ Time Frame: at 18 months ]
    Each of the components of the combined primary outcome, as defined above, analyzed separately As previously demonstrated, bathing and dressing are the first ADL losses, also defined by Katz et al. as the thresholds of disability [17] [18]. A total limitation in bathing and dressing will be considered (each item is coded from 0 - no limitation, to 2 - total limitation).

  5. BADL dependency will be evaluated by the clinician using the BADL scale from Katz [17]. [ Time Frame: at 24 months ]
    Each of the components of the combined primary outcome, as defined above, analyzed separately As previously demonstrated, bathing and dressing are the first ADL losses, also defined by Katz et al. as the thresholds of disability [17] [18]. A total limitation in bathing and dressing will be considered (each item is coded from 0 - no limitation, to 2 - total limitation).

  6. BADL dependency will be evaluated by the clinician using the BADL scale from Katz [17]. [ Time Frame: at 30 months ]
    Each of the components of the combined primary outcome, as defined above, analyzed separately As previously demonstrated, bathing and dressing are the first ADL losses, also defined by Katz et al. as the thresholds of disability [17] [18]. A total limitation in bathing and dressing will be considered (each item is coded from 0 - no limitation, to 2 - total limitation).

  7. Combination of complete BADL dependency in bathing and dressing and/or institutionalization or death [ Time Frame: at inclusion ]

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

    For dependency in bathing and dressing, although it could be considered as less objective, we choose a level of total dependency, easy to assess with very low risk of misinterpretation.


  8. Combination of complete BADL dependency in bathing and dressing and/or institutionalization or death [ Time Frame: at 6 months ]

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

    For dependency in bathing and dressing, although it could be considered as less objective, we choose a level of total dependency, easy to assess with very low risk of misinterpretation.


  9. Combination of complete BADL dependency in bathing and dressing and/or institutionalization or death [ Time Frame: at 12 months ]

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

    For dependency in bathing and dressing, although it could be considered as less objective, we choose a level of total dependency, easy to assess with very low risk of misinterpretation.


  10. Combination of complete BADL dependency in bathing and dressing and/or institutionalization or death [ Time Frame: at 18 months ]

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

    For dependency in bathing and dressing, although it could be considered as less objective, we choose a level of total dependency, easy to assess with very low risk of misinterpretation.


  11. Combination of complete BADL dependency in bathing and dressing and/or institutionalization or death [ Time Frame: at 24 months ]

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

    For dependency in bathing and dressing, although it could be considered as less objective, we choose a level of total dependency, easy to assess with very low risk of misinterpretation.


  12. Combination of complete BADL dependency in bathing and dressing and/or institutionalization or death [ Time Frame: at 30 months ]

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

    For dependency in bathing and dressing, although it could be considered as less objective, we choose a level of total dependency, easy to assess with very low risk of misinterpretation.


  13. Institutionalization with date of entry [ Time Frame: at inclusion ]
    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

  14. Institutionalization with date of entry [ Time Frame: at 6 months ]
    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

  15. Institutionalization with date of entry [ Time Frame: at 12 months ]
    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

  16. Institutionalization with date of entry [ Time Frame: at 18 months ]
    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

  17. Institutionalization with date of entry [ Time Frame: at 24 months ]
    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

  18. Institutionalization with date of entry [ Time Frame: at 30 months ]
    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

  19. Death and date of death [ Time Frame: at inclusion ]
    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

  20. Death and date of death [ Time Frame: at 6 months ]
    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

  21. Death and date of death [ Time Frame: at 12 months ]
    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

  22. Death and date of death [ Time Frame: at 18 months ]
    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

  23. Death and date of death [ Time Frame: at 24 months ]
    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

  24. Death and date of death [ Time Frame: at 30 months ]
    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

  25. the ADL scale [ Time Frame: at inclusion ]

    ADL DE KATZ BATHING :└─┘/2 0 bathes self completely

    1. needs help in bathing only one part of the body
    2. needs help with bathing more than one part of the body or not bathed DRESSING :└─┘ /2

    0 gets clothes and gets completely dressed without assistance

    1 gets clothes and gets dressed without assistance, except for assistance in tying shoes 2 receives assistance in getting clothes or in getting dressed, or stays partly or completely undressed TOILETING :└─┘/2 0 toileting without assistance (may use cane, walker, or wheelchair)

    1 receives assistance 2 doesn't go to room termed " toilet ". TRANSFER:└─┘/2 0 transfer without assistance (may be using cane or walker)

    1. transfer with assistance
    2. doesn't get out of bed. FEEDING :└─┘/2

    0 feeding without help

    1. need help cutting meat or buttering bread
    2. needs total help or requires parenteral feeding. TOTAL : └─┴─┘/10 If the patient has a result of 2 at bathing and or dressing he can't be included at T0.

  26. the ADL scale [ Time Frame: at 6 months ]

    ADL DE KATZ BATHING :└─┘/2 0 bathes self completely

    1. needs help in bathing only one part of the body
    2. needs help with bathing more than one part of the body or not bathed DRESSING :└─┘ /2

    0 gets clothes and gets completely dressed without assistance

    1 gets clothes and gets dressed without assistance, except for assistance in tying shoes 2 receives assistance in getting clothes or in getting dressed, or stays partly or completely undressed TOILETING :└─┘/2 0 toileting without assistance (may use cane, walker, or wheelchair)

    1 receives assistance 2 doesn't go to room termed " toilet ". TRANSFER:└─┘/2 0 transfer without assistance (may be using cane or walker)

    1. transfer with assistance
    2. doesn't get out of bed. FEEDING :└─┘/2

    0 feeding without help

    1. need help cutting meat or buttering bread
    2. needs total help or requires parenteral feeding. TOTAL : └─┴─┘/10 If the patient has a result of 2 at bathing and or dressing he can't be randomized at T6M

  27. the ADL scale [ Time Frame: at 12 months ]

    ADL DE KATZ BATHING :└─┘/2 0 bathes self completely

    1. needs help in bathing only one part of the body
    2. needs help with bathing more than one part of the body or not bathed DRESSING :└─┘ /2

    0 gets clothes and gets completely dressed without assistance

    1 gets clothes and gets dressed without assistance, except for assistance in tying shoes 2 receives assistance in getting clothes or in getting dressed, or stays partly or completely undressed TOILETING :└─┘/2 0 toileting without assistance (may use cane, walker, or wheelchair)

    1 receives assistance 2 doesn't go to room termed " toilet ". TRANSFER:└─┘/2 0 transfer without assistance (may be using cane or walker)

    1. transfer with assistance
    2. doesn't get out of bed. FEEDING :└─┘/2

    0 feeding without help

    1. need help cutting meat or buttering bread
    2. needs total help or requires parenteral feeding. TOTAL : └─┴─┘/10

  28. the ADL scale [ Time Frame: at 18 months ]

    ADL DE KATZ BATHING :└─┘/2 0 bathes self completely

    1. needs help in bathing only one part of the body
    2. needs help with bathing more than one part of the body or not bathed DRESSING :└─┘ /2

    0 gets clothes and gets completely dressed without assistance

    1 gets clothes and gets dressed without assistance, except for assistance in tying shoes 2 receives assistance in getting clothes or in getting dressed, or stays partly or completely undressed TOILETING :└─┘/2 0 toileting without assistance (may use cane, walker, or wheelchair)

    1 receives assistance 2 doesn't go to room termed " toilet ". TRANSFER:└─┘/2 0 transfer without assistance (may be using cane or walker)

    1. transfer with assistance
    2. doesn't get out of bed. FEEDING :└─┘/2

    0 feeding without help

    1. need help cutting meat or buttering bread
    2. needs total help or requires parenteral feeding. TOTAL : └─┴─┘/10

  29. the ADL scale [ Time Frame: at 24 months ]

    ADL DE KATZ BATHING :└─┘/2 0 bathes self completely

    1. needs help in bathing only one part of the body
    2. needs help with bathing more than one part of the body or not bathed DRESSING :└─┘ /2

    0 gets clothes and gets completely dressed without assistance

    1 gets clothes and gets dressed without assistance, except for assistance in tying shoes 2 receives assistance in getting clothes or in getting dressed, or stays partly or completely undressed TOILETING :└─┘/2 0 toileting without assistance (may use cane, walker, or wheelchair)

    1 receives assistance 2 doesn't go to room termed " toilet ". TRANSFER:└─┘/2 0 transfer without assistance (may be using cane or walker)

    1. transfer with assistance
    2. doesn't get out of bed. FEEDING :└─┘/2

    0 feeding without help

    1. need help cutting meat or buttering bread
    2. needs total help or requires parenteral feeding. TOTAL : └─┴─┘/10

  30. the ADL scale [ Time Frame: at 30 months ]

    ADL DE KATZ BATHING :└─┘/2 0 bathes self completely

    1. needs help in bathing only one part of the body
    2. needs help with bathing more than one part of the body or not bathed DRESSING :└─┘ /2

    0 gets clothes and gets completely dressed without assistance

    1 gets clothes and gets dressed without assistance, except for assistance in tying shoes 2 receives assistance in getting clothes or in getting dressed, or stays partly or completely undressed TOILETING :└─┘/2 0 toileting without assistance (may use cane, walker, or wheelchair)

    1 receives assistance 2 doesn't go to room termed " toilet ". TRANSFER:└─┘/2 0 transfer without assistance (may be using cane or walker)

    1. transfer with assistance
    2. doesn't get out of bed. FEEDING :└─┘/2

    0 feeding without help

    1. need help cutting meat or buttering bread
    2. needs total help or requires parenteral feeding. TOTAL : └─┴─┘/10

  31. the MMSE score [ Time Frame: at inclusion ]
    The MMSE score will be assessed by the clinician, the psychologist or the speech therapist according to the habits of the center, using the French version of the MMSE (GRECO version)

  32. the MMSE score [ Time Frame: at 6 months ]
    The MMSE score will be assessed by the clinician, the psychologist or the speech therapist according to the habits of the center, using the French version of the MMSE (GRECO version)

  33. the MMSE score [ Time Frame: at 12 months ]
    The MMSE score will be assessed by the clinician, the psychologist or the speech therapist according to the habits of the center, using the French version of the MMSE (GRECO version)

  34. the MMSE score [ Time Frame: at 18 months ]
    The MMSE score will be assessed by the clinician, the psychologist or the speech therapist according to the habits of the center, using the French version of the MMSE (GRECO version)

  35. the MMSE score [ Time Frame: at 24 months ]
    The MMSE score will be assessed by the clinician, the psychologist or the speech therapist according to the habits of the center, using the French version of the MMSE (GRECO version)

  36. the MMSE score [ Time Frame: at 30 months ]
    The MMSE score will be assessed by the clinician, the psychologist or the speech therapist according to the habits of the center, using the French version of the MMSE (GRECO version)

  37. the number of hospitalizations [ Time Frame: at inclusion ]
    The number of hospitalizations will be assessed using standardized questionnaire, with date (month/year) and duration of hospitalization;

  38. the number of hospitalizations [ Time Frame: at 6 months ]
    The number of hospitalizations will be assessed using standardized questionnaire, with date (month/year) and duration of hospitalization;

  39. the number of hospitalizations [ Time Frame: at 12 months ]
    The number of hospitalizations will be assessed using standardized questionnaire, with date (month/year) and duration of hospitalization;

  40. the number of hospitalizations [ Time Frame: at 18 months ]
    The number of hospitalizations will be assessed using standardized questionnaire, with date (month/year) and duration of hospitalization;

  41. the number of hospitalizations [ Time Frame: at 24 months ]
    The number of hospitalizations will be assessed using standardized questionnaire, with date (month/year) and duration of hospitalization;

  42. the number of hospitalizations [ Time Frame: at 30 months ]
    The number of hospitalizations will be assessed using standardized questionnaire, with date (month/year) and duration of hospitalization;

  43. Pharmacologie treatments consumed by the patient [ Time Frame: at inclusion ]
    All the pharmacologie treatments consumed by the patient will be assessed, allowing to assess psychotropic drug consumption.

  44. Pharmacologie treatments consumed by the patient [ Time Frame: at 6 months ]
    All the pharmacologie treatments consumed by the patient will be assessed, allowing to assess psychotropic drug consumption.

  45. Pharmacologie treatments consumed by the patient [ Time Frame: at 12 months ]
    All the pharmacologie treatments consumed by the patient will be assessed, allowing to assess psychotropic drug consumption.

  46. Pharmacologie treatments consumed by the patient [ Time Frame: at 18 months ]
    All the pharmacologie treatments consumed by the patient will be assessed, allowing to assess psychotropic drug consumption.

  47. Pharmacologie treatments consumed by the patient [ Time Frame: at 24 months ]
    All the pharmacologie treatments consumed by the patient will be assessed, allowing to assess psychotropic drug consumption.

  48. Pharmacologie treatments consumed by the patient [ Time Frame: at 30 months ]
    All the pharmacologie treatments consumed by the patient will be assessed, allowing to assess psychotropic drug consumption.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • New case of AD referring to a CMRR or MC.
  • Diagnosis of probable or possible AD, defined according to the NINCDS-ARDRA criteria
  • Mild to moderate stage, defined by a MMSE score above 15 at the time of pre-inclusion
  • Patients with indication to CI treatment
  • Patients Naïve to CI treatment
  • Patients aged 50 years or more
  • Menopause or effective contraception (for women)
  • Affiliated person or beneficiary of a social security scheme
  • Patients with AD LTI (Long Term Illeness)
  • Patients agree to participate, with free, informed and written consent signed by the patient and his caregiver

Non Inclusion Criteria:

  • Patients diagnosed with Lewy bodies disease, fronto-temporal dementia, or dementia from a cause other than Alzheimer Disease
  • More severe stage of the disease, defined by a MMSE equal or below 15 at the time of inclusion
  • Patients with contraindication to CI treatment
  • Patients residing in an institution at the time of pré-inclusion or randomization
  • Patients with a complete dependency for bathing and dressing at the time of pré-inclusion or randomization ( ADL de Katz, score 2/2 for the item "bathing" and/or "dressing")
  • Patients under tutorship or curatorship, patients unable to express consent
  • Patients with unstable severe general disease compromising the follow-up
  • Patients without caregiver
  • Patients included in another pharmacological trial
  • Pregnant or breastfeeding women

Exclusion Criteria:

  • CI responder patients for whom the MMSE score remained stable or became higher after 6 months of treatment
  • Patients with complete dependency for bathing and dressing at the randomization visit
  • Patients residing in an institution at the randomization visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03454646


Contacts
Contact: Jean-François DARTIGUES, M.D., Ph.D 05 57 82 01 16 jean-francois.dartigues@u-bordeaux.fr
Contact: François TISON, M.D., Ph.D 05 57 82 12 54 francois.tison@chu-bordeaux.fr

Locations
France
CHU d'Amiens Centre Mémoire Ressources Recherche Not yet recruiting
Amiens, France, 80054
Contact: Agnès DEVENDEVILLE    03.22.66.82.40    devendeville.agnes@chu-amiens.fr   
CHU d'Angers Centre Mémoire Ressources Recherche
Angers, France, 49933
CHU de Bastia Centre Mémoire Ressources Recherche Not yet recruiting
Bastia, France, 20604
Contact: Georges RETTALI    04.95.59.18.32    georges.retali@ch-bastia.fr   
CHU de Besançon Centre Mémoire Ressources Recherche
Besançon, France, 25030
CHU de Bordeaux - Service de Neurologie - Centre Mémoire Ressources Recherche - Not yet recruiting
Bordeaux, France, 33076
Contact: Jean-François DARTIGUES    0557820116    jean-françois.dartigues@u-bordeaux.fr   
CHRU Cavale Blanche Service de Gériatrie
Brest, France, 29200
Service de Neuropsychologie Hôpital Neurologique Pierre Wertheimer Not yet recruiting
Bron, France, 69677
Contact: Hélène MOLLION    04.72.35.71.79    helene.mollion@chu-lyon.fr   
CHU Côte de Nacre Service de neurologie et CMRR
Caen, France, 14033
CHU de Clermont Ferrand Centre Mémoire Ressources Recherche
Clermont-Ferrand, France, 63000
Hôpital Pasteur Service de Neurologie
Colmar, France, 68000
CHU de Dijon- CMRR Not yet recruiting
Dijon, France, 21679
Contact: Yannick BEJOT    03.80.29.58.03    yannick.bejot@chu-dijon.fr   
Chu de Grenoble CMRR, Neurologie Not yet recruiting
Grenoble, France, 38043
Contact: Olivier MOREAUD    04 76 76 57 90    omoreaud@chu-grenoble.fr   
Hôpital Roger Salengro CMRR
Lille, France, 59037
CHU Limoges Service de neurologie et CMRR Not yet recruiting
Limoges, France, 87000
Contact: Leslie CARTZ-PIVER    05.55.43.12.15    Lcp.coglim@gmail.com   
AP-HM
Marseille, France
CHU Montpellier Hôpital Gui de Chauliac CMRR Not yet recruiting
Montpellier, France, 34295
Contact: Audrey GABOREAU DE LOUSTAL    04.67.33.60.29    a-gabelle@chu-montpellier.fr   
CHU de Nantes Clinique Neurologique Hôpital GR Laennec Not yet recruiting
Nantes, France, 44093
Contact: Claire BOUTOLEAU    02.40.16.54.22    claire.boutoleaubretonniere@chu-nantes.fr   
Institut Claude Pompidou Centre Mémoire de Ressources et de Recherche Not yet recruiting
Nice, France, 06100
Contact: Renaud David    04.92.03.47.70    claire.paquet@inserm.fr   
APHP Hôpital Broca Not yet recruiting
Paris, France, 75013
Contact: Olivier HANON    01.44.08.35.03    olivier.hanon@brc.aphp.fr   
Hôpital Universitaire de la Pitié Salpêtrière Pavillon François Lhermitte Not yet recruiting
Paris, France, 75013
Contact: Stéphane EPELBAUM    01.42.16.75.22    stephane.epelbaum@psl.aphp.fr   
APHP Groupe Hospitalier Saint Louis Lariboisière Fernand Widal CMRR Not yet recruiting
Paris, France, 75475
Contact: Claire PAQUET    01.40.05.49.54    claire.paquet@inserm.fr   
CHU La Milétrie Pôle de Gériatrie Not yet recruiting
Poitiers, France, 86021
Contact: Marc PACCALIN    05.49.44.44.27    m.paccalin@chu-poitiers.fr   
CHU Reims Hôpital Maison Blanche Court Séjour Gériatrique Not yet recruiting
Reims, France, 51092
Contact: Jean-Luc NOVELLA    03.26.78.44.10    jl.novella@chu-reims.fr   
CHU de Rennes - Hôpital Pontchaillou / Service de Neurologie Not yet recruiting
Rennes, France, 35033
Contact: Serge BELLIARD    02.99.87.30.26    serge.belliard@chu-rennes.fr   
CHU de Rouen Hôpital Charles Nicolle Service Neurologie Not yet recruiting
Rouen, France, 76031
Contact: David Wallon    06.08.97.29.59    david.wallon@chu-rouen.fr   
Chu de Saint-Etienne, CMRR Not yet recruiting
Saint-Étienne, France, 42055
Contact: Isabelle ROUCH    04.77.12.73.98    isabelle.rouch@chu-st-etienne.fr   
Chu de Strasbourg Hôpital Ka Robertsau Pôle de Gériatrie - CMRR Not yet recruiting
Strasbourg, France, 67200
Contact: Frédéric BLANC    03.88.12.86.38    frederic.blanc@chru-strasbourg.fr   
Centre de Recherche Clinique du Gérontopôle Cité de la Santé
Toulouse, France
CHRU de Bretonneau Unité de gérontopsychiatrie Not yet recruiting
Tours, France, 37000
Contact: Thomas DESMIDT    06.68.07.97.06    t.desmidt@chu-tours.fr   
CHU Nancy Service de Gériatrie-CMRR Not yet recruiting
Vandoeuvre les nancy, France, 54511
Contact: Thérèse RIVASSEAU JONVAUX    03.83.15.35.71    t.jonveaux@chu-nancy.fr   
Hospice Civil de Lyon Hôpital des Charpennes Not yet recruiting
Villeurbanne, France, 69100
Contact: Pierre KROLAK SALMON    04.72.43.20.50    pierre.krolak-salmon@chu-lyon.fr   
Sponsors and Collaborators
University Hospital, Bordeaux

Responsible Party: University Hospital, Bordeaux
ClinicalTrials.gov Identifier: NCT03454646     History of Changes
Other Study ID Numbers: CHUBX 2016/27
First Posted: March 6, 2018    Key Record Dates
Last Update Posted: March 6, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Dementia
Tauopathies
Donepezil
Galantamine
Rivastigmine
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents
Parasympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Neuroprotective Agents
Protective Agents